ChoY., JohnsonD.W.Peritoneal dialysis-related peritonitis: towards improving evidence, practices, and outcomes.Am J Kidney Dis2014; 64(2): 278–89.
4.
LanP.G., ClaytonP., JohnsonD.W., McDonaldS.P., BorlaceM., BadveS.V.Duration of haemodialysis following PD cessation in Australia and New Zealand: implications for definitions of technique failure.Perit Dial Int2016. doi: 10.3747/pdi.2015.00218 [Epub ahead of print.]
5.
MortonR.L., SnellingP., WebsterA.C., RoseJ., MastersonR., JohnsonD.W.Dialysis modality preference of patients with CKD and family caregivers: a discrete-choice study.Am J Kidney Dis2012; 60(1): 102–11.
6.
BadveS.V., SmithA., HawleyC.M., JohnsonD.W.Adherence to guideline recommendations for infection prophylaxis in peritoneal dialysis patients.NDT Plus2009; 2(6): 508.
7.
GhaliJ.R., BannisterK.M., BrownF.G., RosmanJ.B., WigginsK.J., JohnsonD.W.Microbiology and outcomes of peritonitis in Australian peritoneal dialysis patients.Perit Dial Int2011; 31(6): 651–62.
8.
JarvisE.M., HawleyC.M., McDonaldS.P., BrownF.G., RosmanJ.B., WigginsK.J.Predictors, treatment, and outcomes of non-Pseudomonas gram-negative peritonitis.Kidney Int2010; 78(4): 408–14.
9.
GovindarajuluS., HawleyC.M., McDonaldS.P., BrownF.G., RosmanJ.B., WigginsK.J.Staphylococcus aureus peritonitis in Australian peritoneal dialysis patients: predictors, treatment, and outcomes in 503 cases.Perit Dial Int2010; 30(3): 311–9.
10.
FahimM., HawleyC.M., McDonaldS.P., BrownF.G., RosmanJ.B., WigginsK.J.Culture-negative peritonitis in peritoneal dialysis patients in Australia: predictors, treatment, and outcomes in 435 cases.Am J Kidney Dis2010; 55(4): 690–7.
11.
FahimM., HawleyC.M., McDonaldS.P., BrownF.G., RosmanJ.B., WigginsK.J.Coagulase-negative staphylococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 936 cases.Nephrol Dial Transplant2010; 25(10): 3386–92.
12.
EdeyM., HawleyC.M., McDonaldS.P., BrownF.G., RosmanJ.B., WigginsK.J.Enterococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 116 cases.Nephrol Dial Transplant2010; 25(4): 1272–8.
13.
BarracloughK., HawleyC.M., McDonaldS.P., BrownF.G., RosmanJ.B., WigginsK.J.Corynebacterium peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 82 cases.Nephrol Dial Transplant2009; 24(12): 3834–9.
14.
BarracloughK., HawleyC.M., McDonaldS.P., BrownF.G., RosmanJ.B., WigginsK.J.Polymicrobial peritonitis in peritoneal dialysis patients in Australia: predictors, treatment, and outcomes.Am J Kidney Dis2010; 55(1): 121–31.
15.
MilesR., HawleyC.M., McDonaldS.P., BrownF.G., RosmanJ.B., WigginsK.J.Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients.Kidney Int2009; 76(6): 622–8.
16.
ChoY., BadveS.V., HawleyC.M., McDonaldS.P., BrownF.G., BoudvilleN.The effects of living distantly from peritoneal dialysis units on peritonitis risk, microbiology, treatment and outcomes: a multi-centre registry study.BMC Nephrol2012; 13: 41.
17.
ChoY., BadveS.V., HawleyC.M., McDonaldS.P., BrownF.G., BoudvilleN.Effects of climatic region on peritonitis risk, microbiology, treatment, and outcomes: a multicenter registry study.Perit Dial Int2013; 33(1): 75–85.
18.
ChoY., BadveS.V., HawleyC.M., McDonaldS.P., BrownF.G., BoudvilleN.Seasonal variation in peritoneal dialysis-associated peritonitis: a multi-centre registry study.Nephrol Dial Transplant2012; 27(5): 2028–36.
19.
McDonaldS.P., CollinsJ.F., RumpsfeldM., JohnsonD.W.Obesity is a risk factor for peritonitis in the Australian and New Zealand peritoneal dialysis patient populations.Perit Dial Int2004; 24(4): 340–6.
20.
JohnsonD.W., ClaytonP., ChoY., BadveS.V., HawleyC.M., McDonaldS.Weekend compared with weekday presentations of peritoneal dialysis-associated peritonitis.Perit Dial Int2012; 32(5): 516–24.
21.
ChoY., BadveS.V., HawleyC.M., McDonaldS.P., BrownF.G., BoudvilleN.Peritoneal dialysis outcomes after temporary haemodialysis transfer for peritonitis.Nephrol Dial Transplant2014; 29(10): 1940–7.
22.
SivaB., HawleyC.M., McDonaldS.P., BrownF.G., RosmanJ.B., WigginsK.J.Pseudomonas peritonitis in Australia: predictors, treatment, and outcomes in 191 cases.Clin J Am Soc Nephrol2009; 4(5): 957–64.
23.
BurkeM., HawleyC.M., BadveS.V., McDonaldS.P., BrownF.G., BoudvilleN.Relapsing and recurrent peritoneal dialysis-associated peritonitis: a multicenter registry study.Am J Kidney Dis58(3): 429–36.
BoudvilleN., KempA., ClaytonP., LimW., BadveS.V., HawleyC.M.Recent peritonitis associates with mortality among patients treated with peritoneal dialysis.J Am Soc Nephrol2012; 23(8): 1398–405.
26.
LiP.K., SzetoC.C., PirainoB., De ArteagaJ.D., FanS.L., FigueiredoA.E.ISPD peritonitis recommendations: 2016 update on prevention and treatment.Perit Dial Int2016; 36(5): 481–508.
27.
PerlJ., DaviesS.J., LambieM., PisoniR.L., McCulloughK., JohnsonD.W.The Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS): unifying efforts to inform practice and improve global outcomes in peritoneal dialysis.Perit Dial Int2016; 36(3): 297–307.
28.
MorrishA.T., HawleyC.M., JohnsonD.W., BadveS.V., PerkovicV., ReidlingerD.M.Establishing a clinical trials network in nephrology: experience of the Australasian Kidney Trials Network.Kidney Int2014; 85(1): 23–30.
29.
JohnsonD.W., BrownF.G., ClarkeM., BoudvilleN., EliasT.J., FooM.W.Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.J Am Soc Nephrol2012; 23(6): 1097–107.
30.
JohnsonD.W., BrownF.G., ClarkeM., BoudvilleN., EliasT.J., FooM.W.The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial.Perit Dial Int2012; 32(5): 497–506.
31.
HowardK., HayesA., ChoY., CassA., ClarkeM., JohnsonD.W.Economic evaluation of neutral-pH, low-glucose degradation product peritoneal dialysis solutions compared with standard solutions: a secondary analysis of the balANZ Trial.Am J Kidney Dis2015; 65(5): 773–9.
32.
JohnsonD.W., BadveS.V., PascoeE.M., BellerE., CassA., ClarkC.Antibacterial honey for the prevention of peritoneal-dialysis-related infections (HONEYPOT): a randomised trial.Lancet Infect Dis2014; 14(1): 23–30.
33.
ZhangL., BadveS.V., PascoeE.M., BellerE., CassA., ClarkC.The effect of exit-site antibacterial honey versus nasal mupirocin prophylaxis on the microbiology and outcomes of peritoneal dialysis-associated peritonitis and exit-site infections: a sub-study of the Honeypot Trial.Perit Dial Int2015; 35(7): 712–21.
34.
ZhangL., HawleyC.M., JohnsonD.W.Focus on peritoneal dialysis training: working to decrease peritonitis rates.Nephrol Dial Transplant2016; 31(2): 214–22.
35.
DalyC., CodyJ.D., KhanI., RabindranathK.S., ValeL., WallaceS.A.Double bag or Y-set versus standard transfer systems for continuous ambulatory peritoneal dialysis in end-stage kidney disease.Cochrane Database Syst Rev2014; 8: Cd003078.
36.
StrippoliG.F., TongA., JohnsonD., SchenaF.P., CraigJ.C.Catheter-related interventions to prevent peritonitis in peritoneal dialysis: a systematic review of randomized, controlled trials.J Am Soc Nephrol2004; 15(10): 2735–46.
37.
StrippoliG.F., TongA., JohnsonD., SchenaF.P., CraigJ.C.Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients.Cochrane Database Syst Rev2004 (4): Cd004679.
PirainoB., BernardiniJ., BrownE., FigueiredoA., JohnsonD.W., LyeW-CISPD position statement on reducing the risks of peritoneal dialysis– related infections.Perit Dial Int2011; 31(6): 614–30.
41.
ChalmersI., GlasziouP.Avoidable waste in the production and reporting of research evidence.Lancet2009; 374(9683): 86–9.
42.
WilkieM.Are quality improvement collaboratives the way forward in peritoneal dialysis?Perit Dial Int2016; 36(1): 3–4.
43.
GrolR., GrimshawJ.From best evidence to best practice: effective implementation of change in patients’ care.Lancet2003; 362(9391): 1225–30.
44.
CampbellD.J., BrownF.G., CraigJ.C., GallagherM.P., JohnsonD.W., KirklandG.S.Assessment of current practice and barriers to antimicrobial prophylaxis in peritoneal dialysis patients.Nephrol Dial Transplant2015 [E-pub ahead of print; doi: 10.1093/ndt/gfv115].
45.
ChidambaramM., BargmanJ.M., QuinnR.R., AustinP.C., HuxJ.E., LaupacisA.Patient and physician predictors of peritoneal dialysis technique failure: a population based, retrospective cohort study.Perit Dial Int2011; 31(5): 565–73.
46.
SchaubelD.E., BlakeP.G., FentonS.S.Effect of renal center characteristics on mortality and technique failure on peritoneal dialysis.Kidney Int2001; 60(4): 1517–24.
47.
HuismanR.M., NieuwenhuizenM.G., Th de CharroF.Patient-related and centre-related factors influencing technique survival of peritoneal dialysis in The Netherlands.Nephrol Dial Transplant2002; 17(9): 1655–60.
48.
JoseM.D., JohnsonD.W., MudgeD.W., TranaeusA., VossD., WalkerR.Peritoneal dialysis practice in Australia and New Zealand: a call to action.Nephrology (Carlton)2011; 16(1): 19–29.
49.
ErsoyF.F.Improving technique survival in peritoneal dialysis: what is modifiable?Perit Dial Int2009; 29(Suppl 2): S74–7.
50.
QamarM., ShethH., BenderF.H., PirainoB.Clinical outcomes in peritoneal dialysis: impact of continuous quality improvement initiatives.Adv Perit Dial2009; 25: 76–9.
ANZDATA Registry38th Report, Chapter 5: Peritoneal Dialysis.Adelaide, Australia: Australia and New Zealand Dialysis and Transplant Registry, 2016.
54.
MudgeD.W., BoudvilleN., BrownF., ClaytonP., DuddingtonM., HoltS.Peritoneal dialysis practice in Australia and New Zealand: a call to sustain the action.Nephrology (Carlton)2016; 21(7): 535–46.
